Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSA single-arm pilot paired a checkpoint drug with targeted radiation in 26 neuroendocrine cancer patients and saw a 35 percent response rate. With no radiation-only group to compare against, and severe side effects in over half of patients, the study cannot show the immune drug added anything.
A TriNetX cohort reports that GLP-1 drugs lowered every measured outcome after liver transplant, including a surgical clot and immune rejection the drugs have no plausible way to prevent. That uniform benefit is the fingerprint of confounding, not proof the drugs save lives.
A Beijing group rebuilt the tip of a fusion-inhibitor lipopeptide by adding one amino acid, restoring potency against the resistant HIV mutants that defeat the class and clearing virus below detection in mice and macaques.
Spinning raises aldosterone, which swells inner-ear fluid and drives motion sickness in rodents. Atrial natriuretic peptide reverses the salt-handling machinery and blocks the response. The work is preclinical, in two rodent species and cultured cells.
In a six-patient first-in-human trial, an albumin-binding upgrade to the neuroendocrine tumor drug Lutathera made the radioactive peptide linger far longer. The kidneys came through fine, but the bone marrow became the organ that capped the dose.
The same desmopressin dose produces anywhere from a quarter to more than triple the standard factor VIII rise, set by which single F8 missense variant a patient carries. A 1,441-person study maps the fourteenfold spread.
A chromogranin A fragment is depleted in Alzheimer's, corticobasal degeneration, and progressive supranuclear palsy brains. Supplementing it cut tau and amyloid pathology in mice by dialing down adrenaline. Cells and mice only, one lab, no human trial.
Lanreotide showed no benefit on directly measured kidney filtration in the LIPS trial. A cheaper creatinine estimate suggested it helped, but the trial's own confirmatory tests did not back that up.
In advanced fatty-liver mice, semaglutide lowered weight and liver-cancer burden but not fibrosis, and pairing it with an investigational antifibrotic (rencofilstat) added no benefit. A null result with a stage-dependent lesson.
A 14-center registry followed 140 children on teduglutide for short bowel syndrome for three years. Parenteral feeding fell by half and about a third weaned off entirely, but the share of underweight children rose from 2.3% to 12.7%.
LL-37, the antimicrobial peptide human cells make to kill bacteria, cut viability, blood-vessel growth, and lung spread in gastric cancer cells and mice by shutting the NF-kB/IL-6 switch. The catch: the same peptide is reported to feed other cancers, and this is cells and mice only.
A Lund University team infused a GIP-receptor or a GLP-1-receptor agonist into mice for a month. The two arms of the incretin drugs remodeled the heart in different directions, and the pattern split by sex.
A short peptide, braced with a hydrocarbon staple, bound CREB at low-nanomolar strength and choked lung cancer cells that had lost the LKB1 tumor suppressor, while mostly sparing cells that kept it. All in a dish. No animal has seen it yet.
A meta-analysis of twelve studies found depression and anxiety scores fell on CGRP-blocking migraine drugs. Almost none of that came from placebo-controlled trials, and the single controlled comparison came up empty.
Researchers fused a small-molecule FAP inhibitor onto a cyclic peptide so the radioligand grips its target twice. The heterobivalent design held in tumors longer and, carrying lutetium-177, slowed tumor growth more than the clinical benchmark FAP-2286 in mice.